The global vaccine adjuvants market is expected to reach USD 758.8 million by 2025, according to a new report by Grand View Research, Inc. The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.
Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.
To request a sample copy or view summary of this report, click the link below:
Further Key Findings From The Report Suggest:
Particulate product type dominated the market in 2016 due to greater efficiency of vaccines, presence of wide range of products, easier availability, and improved safety
Pathogen is anticipated to be the fastest growing segment with a CAGR of 11.9% due to the availability of naturally occurring pathogens used as adjuvants
Among the route of administration, intramuscular held the largest market share in 2016 due to the high immune specificity of vaccines
Infectious disease segment dominated the market in 2016 by application, due to the increasing prevalence of infectious diseases such as hepatitis A, B, C, influenza, meningitis, and others
Cancer is expected to be the fastest growing application segment because of the rising prevalence of cancer and growing R&D activities to treat various types of cancer
Geographically, North America held the largest market share due to increase in favorable government initiatives and presence of well-established healthcare services.
Asia Pacific is estimated to be the fastest growing region over the forecast period with a significant CAGR from 2017 to 2025 due to the presence of huge target population and rise in disposable income
Some of the key players of the market include GlaxoSmithKline plc.; Novavax, Inc.; Adjuvance Technologies, Inc.; SPI Pharma; Agenus, Inc.; CSL Limited; InvivoGen; and Brenntag Biosector
Most of the key participants are focusing on strategies such as mergers & acquisitions, collaborations, and expansion of their product portfolios
In December 2015, SPI Pharma agreed to collaborate with Asahi Kasei Corporation. Both the companies agreed to sell each other’s products in their respective markets: Japan and North America.
Grand View Research has segmented the global vaccine adjuvants market on the basis of type, application, route of administration, and region:
Type Outlook (Revenue, USD Million; 2014 - 2025)
Administration Outlook (Revenue, USD Million; 2014 - 2025)
Application Outlook (Revenue, USD Million; 2014 - 2025)
Regional Outlook (Revenue, USD Million; 2014 - 2025)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.